Evidence map›Paper›PMID 39484452›Full record

ArticlebioRxiv : the preprint server for biology2024

Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.

Jason J Kwon, Julien Dilly, Shengwu Liu, Eejung Kim, Yuemin Bian, Srisathiyanarayanan Dharmaiah, Timothy H Tran, Kevin S Kapner, Seav Huong Ly, Xiaoping Yang and 19 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Jason J KwonDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Julien DillyDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Shengwu LiuDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Eejung KimDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Yuemin BianBroad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Srisathiyanarayanan DharmaiahNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Timothy H TranNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Kevin S KapnerDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Seav Huong LyDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Xiaoping YangBroad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Dana RabaraNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Timothy J WaybrightNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Andrew O GiacomelliHumber Polytechnic, Toronto, ON, Canada.
Andrew L HongDepartment of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA.
Sean MisekDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Belinda WangDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Arvind RaviDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Rameen BeroukhimDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Christopher T LemkeBroad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Kevin M HaigisDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.ORCID 0000-0003-1922-4509
Dominic EspositoNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
David E RootBroad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Dwight V NissleyNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Andrew G StephenNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Frank McCormickNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Dhirendra K SimanshuNCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-9717-4618
William C HahnDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.
Andrew J AguirreDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA.ORCID 0000-0002-0701-6203

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI MALCOLM S. CAPEL · 2018 to 2026
$34.2M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimensU01CA224146 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2017 to 2021
$3.0M
Mechanisms of response and resistance to KRAS inhibition in pancreatic cancerR01CA276268 · NCI · DANA-FARBER CANCER INST · PI Andrew James Aguirre · 2023 to 2026
$2.2M
Pixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0M
Pixel Array Detector for X-ray CrystallographyS10RR029205 · NCRR · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2010 to 2010
$1.8M
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancerK08CA218420 · NCI · DANA-FARBER CANCER INST · PI AGUIRRE, ANDREW JAMES · 2017 to 2021
$886k
Structure and Function of the SHOC2 Holophosphatase Complex in RAS-driven CancerK99CA270290 · NCI · DANA-FARBER CANCER INST · PI KWON, JASON · 2023 to 2023
$147k
NCI NIH HHS 75N91019D00024NCI NIH HHS K08 CA218420NCI NIH HHS K99 CA270290NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA276268NCI NIH HHS U01 CA224146NCRR NIH HHS S10 RR029205NIGMS NIH HHS P30 GM124165NIH HHS S10 OD021527
6 · The paper itself

Abstract

To dissect variant-function relationships in the KRAS oncoprotein, we performed deep mutational scanning (DMS) screens for both wild-type and KRAS

Indexed as

cancerscell transformationdeep mutational scanningKRASstructure-function

Identifiers

PMID39484452
PMCPMC11526993

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.